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Available online 7 June 2016Aims: Brain damage at birth can cause lifelong neurodevelopmental deﬁcits. Recently, stem cell therapies have
been used in several ﬁelds of medicine. We previously reported that CD133+ cells, endothelial progenitor cells
derived from human umbilical cord blood, induce nerve extension in an ex vivo hypoxic-ischemic encephalopa-
thy model. Here, we used an in vivomodel to examine the effect of CD133+ cells in neonatal hypoxic-ischemic
encephalopathy.
Main methods: Hypoxic-ischemic brain lesions were induced in neonatal severe combined immunodeﬁciency
mice using the Rice–Vannucci method. CD133+ cells were administered by intraperitoneal injection 24 h after
injury.
Key ﬁndings: Immunohistochemical analysis revealed that intraperitoneally transplanted CD133+ cells migrate
towards the brain 48 h after injection. Moreover, in CD133+ cell-treated animals, motor function improved
and the brain was protected from the hypoxic-ischemic insult compared with untreated animals.
Signiﬁcance: Our results suggest that CD133+ cells derived from human umbilical cord blood have therapeutic
potential in neonatal hypoxic-ischemic encephalopathy.
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Hypoxic-ischemic encephalopathy (HIE) is a major cause of cerebral
palsy (CP) in full-term infants. Although perinatal medicine has rapidly
progressed, HIE occurs at a rate of about three per thousand live-born
infants, even in developed countries [1]. Of these HIE patients, 15–20%
die in the neonatal period and 30% suffer from neurological deﬁcits in-
cluding CP,mental retardation, learning disabilities, and epilepsy [2]. Al-
though some new treatments have been developed (e.g., hypothermia
and brain hypothermia therapy), they have limited therapeutic effect.
A recent trial of hypothermia treatment reduced the risk of death or
major sensorimotor disability by only 15% [3,4]. Therefore, new and
more effective treatments for HIE urgently need to be developed.
Recently, stemcell therapies have beendeveloped in severalﬁelds of
medicine. Endothelial progenitor cells (EPCs) are one of themajor stem/
progenitor cell subsets with potential for repairing vascular injury and
protecting from ischemic lesions [5,6]. EPCs derived from umbilical
cord blood show higher regenerative potential than adult bone mar-
row-derived EPCs. Because umbilical cord blood is a readily available
source of cells for autotransplantation, EPCs from umbilical cord blood.are advantageous for therapeutic use in infants [7]. We hypothesized
that transplantation of CD133+ cells, an EPC-containing fraction from
umbilical cord blood, may be a useful therapy in neonatal hypoxia-in-
duced brain injury.
Previously, we established an ex vivohypoxic encephalopathymodel
comprising organ co-cultures from the cerebral cortex and spinal cord,
to assess the effects of CD133+ cells derived from human umbilical
cord blood, and conﬁrmed their effect on nerve extension [8]. Hypoxia
markedly suppressed axonal growth in organ co-cultures, and the sup-
pression was signiﬁcantly restored by addition of CD133+ cells to the
culture. CD133+ cells also reduced hypoxia-induced destruction of cor-
tical blood vessels and apoptosis [8]. Here, we further investigated the
therapeutic potential of CD133+ cells using an in vivo neonatal mouse
HIE model.
2. Materials and methods
2.1. Animals
This study was performed in accordance with guidelines from the
Committee of Research Facilities for Laboratory Animal Science at Hiro-
shima University. Postnatal day 7 severe combined immunodeﬁciency
(SCID) mice (C.B-17/lcr-scid/scidJcl; CLEA Japan Inc., Tokyo, Japan)
Table 1
Body weight of hypoxic-ischemic or control (sham-operated) mice, untreated or intraperitoneally injected with CD133+ cells.
Group P7 P28 P35 P42 P49 P56
Sham-operated 3.6 ± 0.1 15.4 ± 0.4 17.6 ± 0.8 20.1 ± 0.6 21.1 ± 0.6 22.7 ± 0.7
HI 3.8 ± 0.2 12.8 ± 0.8a 14.0 ± 0.4b 14.6 ± 0.6c 15.8 ± 0.6d 16.7 ± 0.6e
CD133+ 3.8 ± 0.2 12.8 ± 1.0f 14.9 ± 0.9g 16.4 ± 0.9 17.6 ± 1.0 18.5 ± 1.1
Body weight is in grams (mean ± SE). Postnatal day 7 (P7) = day of surgery, P28 = day of ﬁrst rotarod test.
a P= 0.015,
b P= 0.002,
c P b 0.001,
d P b 0.001
e P b 0.001
f P= 0.014
g P= 0.015
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used immunocompromised mice in order to suppress immunological
reactions due to xenotransplantation.
2.2. Hypoxic-ischemic model
The Rice–Vannuccimodel [9,10]was applied to establish hypoxia-is-
chemia in neonatal SCID mice. Unilateral hypoxic-ischemic cerebral
damage was induced in 7-day-old SCID mice [11] by permanent occlu-
sion of the left common carotid artery under anesthesia. There is com-
pelling evidence that postnatal day 7 mice have brain maturity
equivalent to that of third trimester human fetuses [12]. After surgery,
pups were allowed to recover from anesthesia in their home cages for
1 h. Pups with unilateral carotid artery occlusion were then exposed
to 8% O2/92% N2 for 30 min at 34 °C (ambient temperature) [13,14].
Twenty-four hours after the hypoxic-ischemic insult, pups received
1 × 105 human umbilical cord blood-derived CD133+ cells (in a volume
of 100 μL 0.9% sodium chloride) by intraperitoneal injection. Pups from
ﬁve litters were randomly assigned to three experimental groups: (1)
sham-operated group (sham-operated animals in which the left com-
mon carotid artery was exposed but not ligated, n = 7); (2) HI group
(hypoxic-ischemic insult and 100 μL 0.9% sodium chloride injection as
sham injection, n=7); and (3) CD133+ group (hypoxic-ischemic insult
and CD133+ cell injection, n = 8). There was no difference in body
weight between the three groups on postnatal day 7, but the mice in
the HI group were signiﬁcantly smaller than sham-operated mice on
postnatal day 28 and thereafter. The weight of animals in the CD133+Fig. 1.CD133+ cellmigration to the hypoxic-ischemic lesion site. P7micewere exposed to
hypoxia-ischemia according to the Levinemethod, followed by intraperitoneal injection of
CD133+ cells. CD133+ cells were identiﬁed in the brain by immunohistochemical
detection using anti- HLA-DR α-chain surface antigen. Scale bars: 50 μm. Magniﬁcation:
×400.group was signiﬁcantly lower than those of the sham-operated group
on postnatal days 28 and 35; however, there was no signiﬁcant differ-
ence between these two groups on postnatal day 42 and thereafter.
There was no signiﬁcant difference in body weight between the
CD133+ and HI groups (Table 1).
2.3. Isolation and preparation of human CD133+ cells
The protocol used was approved by the Hiroshima University Re-
search Ethics Committee, and informed consent was obtained from all
participants. Human CD133+ cells were prepared from freshly obtained
human umbilical cord blood, as described in our previous report [15].
Only full-term umbilical cord blood was used because lower numbers
of endothelial colonies are generated from preterm compared with
term umbilical cord blood [16]. Umbilical cord blood mononuclear
cells were isolated by density-gradient centrifugation of buffy coats
using histopaque1077 (Sigma-Aldrich, Oakville, Canada). CD133+ cells
were puriﬁed frommononuclear cells using anti-CD133monoclonal an-
tibody-conjugated microbeads (CD133 MicroBead Kit; Miltenyi Biotec,
Bergisch-Gladbach, Germany) and a magnetically activated cell sorter
(auto-MACSpro; Miltenyi Biotec), following the manufacturer's proto-
col. Isolated CD133+ cells were suspended in freezing medium
(CELLBANKER; Zenoaq, Fukushima, Japan) and cryopreserved until use.
2.4. Motor function analysis
To evaluate motor function, the rotarod test was performed every
7 days between postnatal days 28 and 56. The rotarod test is commonly
used for determining motor coordination in rodents [17]. When placedFig. 2. Performance of hypoxic-ischemic lesioned mice on the rotarod test. P7 mice were
exposed to hypoxia-ischemia according to the Levine method, followed by
intraperitoneal injection of CD133+ cells. The rotarod test was performed every 7 days.
The time spent on the rotarod was plotted for each group. △: sham-operated group
(n = 7); ○: HI group (n = 7); ●: CD133+ group (n = 8). *P = 0.035, **P = 0.027,
***P= 0.009. Data are expressed as mean ± SE.
Fig. 3. Brain damage after hypoxic-ischemic insult. P7 mice were exposed to hypoxia-ischemia according to the Levine method, followed by intraperitoneal injection of CD133+ cells.
Cerebral hemisphere coronal sections were obtained at the level of the optic chiasm (A–C) and hippocampus (D–F) in sham-operated (A, D), HI (B, E), and CD133+ groups (C, F) at
postnatal day 42. (G) Higher-magniﬁcation image of the cystic lesion in (E), which shows several macrophage foci (arrows). (H) Higher-magniﬁcation image of the cystic lesion in (F)
showing no macrophages. Scale bars, (A–F): 200 μm; (G, H): 100 μm.
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the rod. The rotation speed of the rod was ﬁxed at 15 rpm. The mice
rested in their cage for 20min between each trial. Themean time (max-
imum 5 min) for each mouse on the rotarod was determined from ﬁve
trials. After completion of the rotarod test, brains were collected on
postnatal days 42 or 56 for histological analysis.
2.5. Histological examination
After the rotarod test on postnatal days 42 and 56, animals in each
group were deeply anesthetized with diethyl ether, and the brains re-
moved (sham-operated group, n = 7; HI group, n = 7; and CD133+
group, n = 8). The specimens obtained on day 42 were ﬁxed with 4%
paraformaldehyde and parafﬁn embedded. Four-micrometer-thick sec-
tions were cut and stained with hematoxylin and eosin or by the
Klüver–Barreramethod [18]. Brains obtained on day 56were immersed
in SCEM gel (Section Lab, Hiroshima, Japan) and completely frozenwith
the gel in cooled hexane. Embedded brains were sectioned coronally at8-μm thickness, according to Kawamoto's ﬁlmmethod [19]. Lesion sizes
were estimated after Klüver–Barrera staining, which shows myelinated
ﬁber tracts in blue and nerve cell bodies in violet. Lesion size was deter-
mined bymeasuring the hemispheric area of the brain in sections at two
deﬁned coronal levels (the optic chiasm and hippocampus) using Image
J software [20]. The ratio of left to right cerebral hemispheric area was
measured to determine atrophy of the lesioned hemisphere. In addition,
the sizes in hippocampus, striatum and thalamus were compared.
2.6. Immunohistochemistry
As previously described [21], we also examined parafﬁn-embedded
sections by immunohistochemistry using the following primary anti-
bodies:mousemonoclonal antibodies against human leukocyte antigen
class II (HLA-DR) α-chain (Dako, Hamburg, Germany; 1:200), α-
smoothmuscle actin (anti-α-SMA; Funakosi, Tokyo, Japan; 1: 200), rab-
bit polyclonal antibodies against Iba1 (Wako, Osaka, Japan; 1:500),
cleaved caspase 3 (Cell Signaling Technology, Danvers, MA; 1:200)
Fig. 4. Reactive astrocytosis (A, C) and inﬁltration ofmicroglia (arrowheads) andmacrophages (arrows) (B, D) in and around the cystic lesion inHIE (A, B) and CD133+ (C, D) groups. A, C:
GFAP immunostain. B, D: Iba1 immunostain. Scale bars, (A–D): 50 μm.
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dothelium was stained by ﬂuorescein Isolectin B4 (IB4; 1:100, Vector).
The sections were subjected to immunohistochemical processing
using the avidin–biotin–peroxidase complexmethodwith diaminoben-
zidine. These assessments were performed on slides without knowl-
edge of animal's identity by two neuropathologists (Yasuo Miki and
Koichi Wakabayashi). Since there are no immunohistochemical
markers to distinguish between activatedmicroglia and inﬁltratedmac-
rophages [22], we identiﬁed these two cell types morphologically: acti-
vated microglia were deﬁned as small rod cells with wavy, branching
processes and inﬁltrated macrophages were deﬁned as round cells
with abundant granular and vacuolated cytoplasm.
2.7. Statistical analysis
Values were expressed as mean ± standard error. Statistical differ-
ences between two groups were assessed using the Student t-test.
Data of between three groups were analyzed using two-way ANOVA
followed by the appropriate post hoc test (Student–Newman–Keuls).
P-values less than 0.05 were considered to be statistically signiﬁcant.
3. Results
3.1. CD133+ cell migration to the brain
Intraperitoneally transplanted CD133+ cells were
immunohistochemically detected in the lesioned hemisphere at 48 h
after transplantation (Fig. 1). The number of detectable CD133+ cells
peaked at 96 h after transplantation and declined thereafter. Only a
few CD133+ cells were detectable in the non-lesioned hemisphere.
3.2. Analysis of motor function
To examine motor function, the rotarod test was performed every
7 days between postnatal days 28 and 56. Fig. 2 shows the latencybefore falling from the rotarod. Motor function was signiﬁcantly im-
paired in the HI group compared with the sham-operated group (P =
0.010) on postnatal day 42. Moreover, motor function was signiﬁcantly
improved in the CD133+ group compared with the HI group (P =
0.038) on postnatal day 42. Signiﬁcant differences were also observed
between the HI and CD133+ groups on postnatal days 49 (P= 0.037)
and 56 (P= 0.019).
3.3. Histological analysis of the brain
Histopathological examination revealed no obvious abnormalities in
the brains of sham-operated mice on postnatal day 42 (Fig. 3A and D).
After hypoxic-ischemic insult, infarction was observed in the
frontoparietal region, caudate-putamen complex, and hippocampus.
Large cystic lesions were found in the left hemisphere (Fig. 3B and E).
These cysts contained several foci of macrophages and reactive astro-
cytes, and microglia were found in the surrounding area (Figs. 3G and
4A,B). These macrophages and microglia were immunopositive for
Iba1 (Fig. 4B). In the CD133+ group, cystic lesions with reactive
astrocytes and microglia were also observed (Fig. 3H and Fig. 4C, D).
No apoptotic cells were identiﬁed by cleaved caspase 3 immunohisto-
chemistry in the surrounding area in both the HI and CD133+ groups.
However, the cystic lesions in the CD133+ group were much smaller
than those in the HI group. In addition, no or only few macrophages
were found in the CD133+ group (Fig. 3H and Fig. 4D).
Left (lesioned) and right (non-lesioned) hemisphere size was ap-
proximately the same in the sham-operated group at postnatal day 56.
In the HI group, the lesioned hemisphere area was approximately 70%
that of the non-lesioned hemisphere (P = 0.005). In the CD133+
group, the lesioned hemisphere area was approximately 90% that of
the non-lesioned hemisphere. The ratio of lesioned to non-lesioned
hemisphere area in the CD133+ group was signiﬁcantly higher than in
the HI group (P=0.004) (Fig. 5). The hippocampus was speciﬁcally af-
fected in the lesioned hemisphere in the HI and CD133+ groups
(P b 0.0001). Damage to the striatum was detectable, but it was not
Fig. 5.Ratio of right/left hemispheres. The ratios of left (lesioned) to right (non-lesioned) hemisphereweremeasured using ImageJ software, to evaluate brain damage onpostnatal day 56.
A: Comparison of total area of each hemisphere (*P= 0.005, **P= 0.004), B: Comparison of each hippocampus, (*P= 0.001, **P= 0.006), C: Klüver–Barrera stain of hippocampus, D:
Comparison of each striatum (*P= 0.004, **P= 0.026), E: Klüver–Barrera stain of striatum, F: Comparison of each thalamus (*P= 0.015), G: Klüver–Barrera stain of thalamus. Data
are expressed mean ± SE. Scale bars, (C, E, F): 500 μm.
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groups (P= 0.001). Moderate damage was also observed in the thala-
mus (P= 0.042).
To examine brain vessels, brain sections at postnatal day 56 were
immunohistochemically stained with anti-isolectin B4 and anti-α-
SMA antibodies. There were no signiﬁcant differences between the
three groups in number or total length of blood vessels (Table 2).
4. Discussion
Here,we have demonstrated that CD133+ cells derived from human
umbilical cord blood protect mouse brain from neonatal hypoxic-ische-
mic injury. Our conclusion is based on the following observations: (1)
CD133+ cells migrate from the abdominal cavity to damaged brain;
(2) motor function is recovered in animals with transplanted CD133+cells; and (3) lesion size in the CD133+ group is smaller compared
with the HI group.
Asahara et al. ﬁrst described EPCs in 1997 [5]. The CD133 antigen
is expressed on the surface of EPCs, hematopoietic stem cells, and
very small embryonic-like stem cells [23]. The therapeutic effects of
EPCs in post-ischemic myocardial regeneration and adult cerebral
infarction have previously been investigated [24,25]. EPCs induce neo-
vascularization and inhibit myocardial cell apoptosis, and these beneﬁ-
cial effects play an important role in improvement of myocardial
function [26,27]. Additionally, EPCs accelerate functional recovery in
both in vivo and ex vivo rat spinal cord injury studies [28,29]. During
the regenerative period, EPCs speciﬁcally migrate to the injured endo-
thelium and damaged vascular and ischemic organs [30], which
prompted us to determine if EPCs can be a useful and safe cell therapy
for neonatal HIE.
Fig. 5 (continued).
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jury characteristically leads to an extensive unilateral lesion in the cere-
bral cortex, basal ganglia, and hippocampus, which explains the loss of
motor coordination and learning ability. HI mice had a lower body
weight compared with sham-operated group. The body weight of
CD133 mice were lower than sham-operated mice until postnatal day
35, however there was no difference in body weight between these
two groups from postnatal day 42 and thereafter. Furthermore, using
this model we show that CD133+ cells improve motor function by
protecting the brain from hypoxic-ischemic injury-induced damage, al-
though the underlying mechanisms of this effect have not yet been de-
termined. CD133+ cells are able to differentiate into neural cells in vitro
[31], but few transplanted stem cells differentiate into vascular endo-
thelial cells and neurons in ex vivo [32] and in vivo [33]mouse brain.
Using an in vivo neonatal hypoxic-ischemic mouse model, Van
Velthoven et al. reported that cell replacement appears to be a rare or
absent event [34]. Beneﬁcial effects (such as functional recoveryTable 2
Length and number of brain blood vessels in hypoxic-ischemic or control (sham-operat-
ed) mice, untreated or intraperitoneally injected with CD133+ cells.
Group Length of vessels (mm/mm2)
Number of vessels
(/mm2)
Sham-operated 0.97 ± 0.15 169.57 ± 9.66
HI 1.03 ± 0.12 171.14 ± 17.56
CD133+ 0.76 ± 0.13 145.50 ± 20.83
Vascular endothelial cells were speciﬁcally stained with anti-isolectin B4, and vascular
smooth muscle cells with anti-α-SMA. The length and number of blood vessels stained
only with anti-isolectin B4 were measured (mean ± SE).following cell transplantation) involve multiple mechanisms including
angiogenesis, and neuroprotective and anti-inﬂammatory effects [35].
While we previously reported that CD133+ cells reduce hypoxia-in-
duced damage of cortical blood vessels in organ co-cultures [8] in our
present in vivo study, the number and length of blood vessels did not
change using transplanted CD133+ cells. The beneﬁcial effects of
transplanted cells are suggested to be mediated by production of vari-
ous neurotrophic factors [6], including nerve growth factor (NGF),
brain-derived neurotrophic factor (BDNF), glial cell line-derived neuro-
trophic factor (GDNF), and neurotrophin-3 [36]. Correspondingly, BDNF
and NGF block caspase-3-mediated apoptosis and microglial activation
in ischemic brain, and these neuroprotective factors may improve the
microenvironment of injured brain tissue. Cell transplantation signiﬁ-
cantly reduces the number of activated microglia [37]. Microglia activa-
tion increases production of cytokines such as tumor necrosis factor-α
and interleukin-1β, which appear to be involved in apoptosis of
premyelinating oligodendrocytes and cell damage [38]. Microglia also
produce anti-inﬂammatory cytokines and it is disturbances in the bal-
ance between pro- and anti-inﬂammatory cytokines that directs pro-ol-
igodendrocyte precursors to differentiate into astrocytes, and not
oligodendrocytes, thus affecting subsequent myelination [39,40].
Human umbilical cord blood cells secrete the interleukins, IL-6, IL-8,
and IL-10, which are known to exert anti-inﬂammatory effects in vivo
[41]. Thus the human umbilical cord cells contribute to restoration of
the pro-/anti-inﬂammatory cytokine balance, and induce protection.
One limitation of this study was that we were required to use immuno-
deﬁcientmice for the HIEmodel to avoid inducing an immune response
through the administration of human cells. Therefore, it is unknown
whether similar results are obtained to normal mice.
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grate to the lesioned brain, and that the chemokine stromal-derived fac-
tor-1α (SDF-1α) and its receptor, chemokine receptor type 4 (CXCR4),
play important roles in trafﬁcking transplanted cells [42–45].
Transplanted stem cells migrate to the brain 24 h after either intraperi-
toneal or intravascular administration, but appear to disappear from the
brain a few weeks after administration [46,47]. In the present study,
CD133+ cells exhibited a similar pattern of behavior. The optimal
route, timing, and cell number for transplantation must be determined
before cell therapy using EPCs can be applied to neonatal HIE. For ische-
mic heart disease in adults, EPCs are injected directly into themyocardi-
um during coronary artery bypass grafting [48] and their effects are
dependent on cell number [49]. For treatment of neonatal HIE, we intra-
peritoneally transplanted cells to avoid cerebral injury caused by direct
administration of EPCs to the brain. Intravenous [50], intranasal [47],
and intrathecal [51] administration have also been performed, but re-
sult in cells becoming trapped in other organs [50]. It is therefore neces-
sary to develop a safe and effective administration route for introducing
cell therapies for neonatal HIE. As for the timing of administration, neo-
natal animal studies suggest transplantation proximal to the time of in-
jury provides better therapeutic effects [33].
Hypoxic-ischemic encephalopathy is a leading cause of neonatal
death and neurological disability. However, current treatments such as
hypothermia have limited therapeutic effect. The techniques of
neurotransplantation and neuroregeneration, which replace and repair
injured cells, are still experimental [52]. Cell therapy using umbilical
cord blood cells was reported to have a good safety proﬁle in a clinical
trial for the treatment of neonatal HIE; however, this trial is ongoing
and efﬁcacy has not yet been demonstrated [53]. The major advantages
of human umbilical cord blood cells are their availability, safety, imma-
turity, and heterogeneous properties.
5. Conclusions
Although further studies are required to determine the precise
mechanisms underlying the effects of CD133+ cells on protection
from brain damage induced by a hypoxic-ischemic insult, our results
suggest the possibility of a novel treatment for neonatal HIE.
Acknowledgments
This work was performed at the Analysis Center of Life Science, Nat-
ural Science Center for Basic Research and Development, Hiroshima
University.
Conﬂicts of interest/disclosure statement: The authors declare that
there are no conﬂicts of interest.
References
[1] M.V. Johnston, A. Fatemi, M.A. Wilson, F. Northington, Treatment advances in neo-
natal neuroprotection and neurointensive care, Lancet Neurol. 10 (2011) 372–382.
[2] M. Shinoyama, M. Ideguchi, H. Kida, K. Kajiwara, Y. Kagawa, Y. Maeda, S. Nomura, M.
Suzuki, Cortical region-speciﬁc engraftment of embryonic stem cell-derived neural
progenitor cells restores axonal sprouting to a subcortical target and achieves
motor functional recovery in a mouse model of neonatal hypoxic-ischemic brain in-
jury, Front. Cell. Neurosci. 7 (2013) 128.
[3] S. Shankaran, A.R. Laptook, R.A. Ehrenkranz, J.E. Tyson, S.A. McDonald, E.F. Donovan,
A.A. Fanaroff, W.K. Poole, L.L. Wright, R.D. Higgins, N.N. Finer, W.A. Carlo, S. Duara,
W. Oh, C.M. Cotten, D.K. Stevenson, B.J. Stoll, J.A. Lemons, R. Guillet, A.H. Jobe, H.
National Institute of Child, N. Human Development Neonatal Research, Whole-
body hypothermia for neonates with hypoxic-ischemic encephalopathy, N. Engl. J.
Med. 353 (2005) 1574–1584.
[4] S.E. Jacobs, C.J. Morley, T.E. Inder, M.J. Stewart, K.R. Smith, P.J. McNamara, I.M.
Wright, H.M. Kirpalani, B.A. Darlow, L.W. Doyle, C. Infant Cooling Evaluation,
Whole-body hypothermia for term and near-term newborns with hypoxic-ische-
mic encephalopathy: a randomized controlled trial, Arch. Pediatr. Adolesc. Med.
165 (2011) 692–700.
[5] T. Asahara, T. Murohara, A. Sullivan, M. Silver, R. van der Zee, T. Li, B. Witzenbichler,
G. Schatteman, J.M. Isner, Isolation of putative progenitor endothelial cells for angio-
genesis, Science 275 (1997) 964–967.[6] C.T. van Velthoven, A. Kavelaars, F. van Bel, C.J. Heijnen, Regeneration of the ische-
mic brain by engineered stem cells: fuelling endogenous repair processes, Brain
Res. Rev. 61 (2009) 1–13.
[7] T. Murohara, S. Kamijikkoku, T. Honda, Increased circulating soluble intercellular ad-
hesion molecule-1 in acute myocardial infarction: a possible predictor of reperfu-
sion ventricular arrhythmias, Crit. Care Med. 28 (2000) 1861–1864.
[8] N. Tanaka, N. Kamei, T. Nakamae, R. Yamamoto, M. Ishikawa, H. Fujiwara, H.
Miyoshi, T. Asahara, M. Ochi, Y. Kudo, CD133+ cells from human umbilical cord
blood reduce cortical damage and promote axonal growth in neonatal rat organ
co-cultures exposed to hypoxia, Int. J. Dev. Neurosci. 28 (2010) 581–587.
[9] J.E. Rice 3rd, R.C. Vannucci, J.B. Brierley, The inﬂuence of immaturity on hypoxic-is-
chemic brain damage in the rat, Ann. Neurol. 9 (1981) 131–141.
[10] S. Levine, Anoxic-ischemic encephalopathy in rats, Am. J. Pathol. 36 (1960) 1–17.
[11] B. Clancy, R.B. Darlington, B.L. Finlay, Translating developmental time across mam-
malian species, Neuroscience 105 (2001) 7–17.
[12] H. Hagberg, D. Peebles, C. Mallard, Models of white matter injury: comparison of in-
fectious, hypoxic-ischemic, and excitotoxic insults, Ment. Retard. Dev. Disabil. Res.
Rev. 8 (2002) 30–38.
[13] N. Rodriguez-Alvarez, E.M. Jimenez-Mateos, M. Dunleavy, J.L. Waddington, G.B.
Boylan, D.C. Henshall, Effects of hypoxia-induced neonatal seizures on acute hippo-
campal injury and later-life seizure susceptibility and anxiety-related behavior in
mice, Neurobiol. Dis. 83 (2015) 100–114.
[14] X.B. Liu, Y. Shen, D.E. Pleasure, W. Deng, The vulnerability of thalamocortical circuit-
ry to hypoxic-ischemic injury in a mouse model of periventricular leukomalacia,
BMC Neurosci. 17 (2016) 2.
[15] H. Muramatsu, F. Katsuoka, K. Toide, Y. Shimizu, S. Furusako, M. Yamamoto, Nrf2 de-
ﬁciency leads to behavioral, neurochemical and transcriptional changes in mice,
Genes Cells 18 (2013) 899–908.
[16] M.J. Javed, L.E. Mead, D. Prater, W.K. Bessler, D. Foster, J. Case, W.S. Goebel, M.C.
Yoder, L.S. Haneline, D.A. Ingram, Endothelial colony forming cells and mesenchy-
mal stem cells are enriched at different gestational ages in human umbilical cord
blood, Pediatr. Res. 64 (2008) 68–73.
[17] R.M. Deacon, Measuring motor coordination in mice, J. Vis. Exp. (2013) e2609,
http://dx.doi.org/10.3791/2609.
[18] H. Kluver, E. Barrera, A method for the combined staining of cells and ﬁbers in the
nervous system, J. Neuropathol. Exp. Neurol. 12 (1953) 400–403.
[19] T. Kawamoto, Use of a new adhesive ﬁlm for the preparation of multi-purpose fresh-
frozen sections from hard tissues, whole-animals, insects and plants, Arch. Histol.
Cytol. 66 (2003) 123–143.
[20] C.A. Schneider, W.S. Rasband, K.W. Eliceiri, NIH image to ImageJ: 25 years of image
analysis, Nat. Methods 9 (2012) 671–675.
[21] Y. Miki, K. Tanji, F. Mori, J. Utsumi, H. Sasaki, A. Kakita, H. Takahashi, K.Wakabayashi,
Alteration of Upstream Autophagy-Related Proteins (ULK1, ULK2, Beclin1, VPS34
and AMBRA1) in Lewy Body Disease(Brain Pathol) 2015, http://dx.doi.org/10.
1111/bpa.12297.
[22] D. Hambardzumyan, D.H. Gutmann, H. Kettenmann, The role of microglia and
macrophages in glioma maintenance and progression, Nat. Neurosci. 19
(2016) 20–27.
[23] J. Ratajczak, M. Kucia, K. Mierzejewska, W. Marlicz, Z. Pietrzkowski, W.Wojakowski,
N.J. Greco, M. Tendera, M.Z. Ratajczak, Paracrine proangiopoietic effects of human
umbilical cord blood-derived puriﬁed CD133+ cells—implications for stem cell
therapies in regenerative medicine, Stem Cells Dev. 22 (2013) 422–430.
[24] M. Meregalli, A. Farini, M. Belicchi, Y. Torrente, CD133(+) cells isolated from various
sources and their role in future clinical perspectives, Expert. Opin. Biol. Ther. 10
(2010) 1521–1528.
[25] R. Flores-Ramirez, A. Uribe-Longoria, M.M. Rangel-Fuentes, P. Gutierrez-Fajardo, R.
Salazar-Riojas, D. Cervantes-Garcia, J.H. Trevino-Ortiz, G.J. Benavides-Chereti, L.P.
Espinosa-Oliveros, R.H. Limon-Rodriguez, R. Monreal-Puente, J.L. Gonzalez-
Trevino, A. Rojas-Martinez, Intracoronary infusion of CD133+ endothelial progeni-
tor cells improves heart function and quality of life in patients with chronic post-in-
farct heart insufﬁciency, Cardiovasc. Revasc. Med. 11 (2010) 72–78.
[26] A. Kawamoto, H.C. Gwon, H. Iwaguro, J.I. Yamaguchi, S. Uchida, H. Masuda, M. Silver,
H. Ma, M. Kearney, J.M. Isner, T. Asahara, Therapeutic potential of ex vivo expanded
endothelial progenitor cells for myocardial ischemia, Circulation 103 (2001)
634–637.
[27] A. Kawamoto, T. Tkebuchava, J. Yamaguchi, H. Nishimura, Y.S. Yoon, C. Milliken, S.
Uchida, O. Masuo, H. Iwaguro, H. Ma, A. Hanley, M. Silver, M. Kearney, D.W.
Losordo, J.M. Isner, T. Asahara, Intramyocardial transplantation of autologous endo-
thelial progenitor cells for therapeutic neovascularization of myocardial ischemia,
Circulation 107 (2003) 461–468.
[28] N. Kamei, S.M. Kwon, C. Alev, K. Nakanishi, K. Yamada, H. Masuda, M. Ishikawa, A.
Kawamoto, M. Ochi, T. Asahara, Ex-vivo expanded human blood-derived CD133+
cells promote repair of injured spinal cord, J. Neurol. Sci. 328 (2013) 41–50.
[29] H. Sasaki, M. Ishikawa, N. Tanaka, K. Nakanishi, N. Kamei, T. Asahara, M. Ochi, Ad-
ministration of human peripheral blood-derived CD133+ cells accelerates function-
al recovery in a rat spinal cord injury model, Spine (Phila Pa 1976) 34 (2009)
249–254.
[30] M. Hristov, W. Erl, P.C. Weber, Endothelial progenitor cells: mobilization, differenti-
ation, and homing, Arterioscler. Thromb. Vasc. Biol. 23 (2003) 1185–1189.
[31] T. Tondreau, N. Meuleman, A. Delforge, M. Dejeneffe, R. Leroy, M. Massy, C. Mortier,
D. Bron, L. Lagneaux, Mesenchymal stem cells derived from CD133-positive cells in
mobilized peripheral blood and cord blood: proliferation, Oct4 expression, and plas-
ticity, Stem Cells 23 (2005) 1105–1112.
[32] R. Yamamoto, M. Ishikawa, N. Tanaka, N. Kamei, K. Nakanishi, H. Sasaki, T. Nakamae,
Y. Mochizuki, T. Asahara, M. Ochi, CD133+ cells from human peripheral blood pro-
mote corticospinal axon regeneration, Neuroreport 19 (2008) 799–803.
115Y. Kidani et al. / Life Sciences 157 (2016) 108–115[33] C. Meier, J. Middelanis, B. Wasielewski, S. Neuhoff, A. Roth-Haerer, M. Gantert, H.R.
Dinse, R. Dermietzel, A. Jensen, Spastic paresis after perinatal brain damage in rats
is reduced by human cord blood mononuclear cells, Pediatr. Res. 59 (2006)
244–249.
[34] C.T. van Velthoven, A. Kavelaars, F. van Bel, C.J. Heijnen, Mesenchymal stem cell
treatment after neonatal hypoxic-ischemic brain injury improves behavioral out-
come and induces neuronal and oligodendrocyte regeneration, Brain Behav.
Immun. 24 (2010) 387–393.
[35] F. Wang, N. Maeda, T. Yasuhara, M. Kameda, E. Tsuru, T. Yamashita, Y. Shen, M.
Tsuda, I. Date, Y. Sagara, The therapeutic potential of human umbilical cord blood
transplantation for neonatal hypoxic-ischemic brain injury and ischemic stroke,
Acta Med. Okayama 66 (2012) 429–434.
[36] P. Lu, L.L. Jones, E.Y. Snyder, M.H. Tuszynski, Neural stem cells constitutively secrete
neurotrophic factors and promote extensive host axonal growth after spinal cord in-
jury, Exp. Neurol. 181 (2003) 115–129.
[37] P.M. Pimentel-Coelho, E.S. Magalhaes, L.M. Lopes, L.C. de Azevedo, M.F. Santiago, R.
Mendez-Otero, Human cord blood transplantation in a neonatal rat model of hypox-
ic-ischemic brain damage: functional outcome related to neuroprotection in the
striatum, Stem Cells Dev. 19 (2010) 351–358.
[38] C. Kaur, G. Rathnasamy, E.A. Ling, Roles of activated microglia in hypoxia induced
neuroinﬂammation in the developing brain and the retina, J. NeuroImmune
Pharmacol. 8 (2013) 66–78.
[39] J.M. Bain, A. Ziegler, Z. Yang, S.W. Levison, E. Sen, TGFbeta1 stimulates the over-pro-
duction of white matter astrocytes from precursors of the “brain marrow” in a ro-
dent model of neonatal encephalopathy, PLoS One 5 (2010), e9567.
[40] E. Rocha-Ferreira, M. Hristova, Antimicrobial peptides and complement in neonatal
hypoxia-ischemia induced brain damage, Front. Immunol. 6 (2015) 56.
[41] M.B. Newman, A.E. Willing, J.J. Manresa, C.D. Sanberg, P.R. Sanberg, Cytokines pro-
duced by cultured human umbilical cord blood (HUCB) cells: implications for
brain repair, Exp. Neurol. 199 (2006) 201–208.
[42] K. Rosenkranz, S. Kumbruch, K. Lebermann, K. Marschner, A. Jensen, R. Dermietzel,
C. Meier, The chemokine SDF-1/CXCL12 contributes to the 'homing' of umbilical
cord blood cells to a hypoxic-ischemic lesion in the rat brain, J. Neurosci. Res. 88
(2010) 1223–1233.
[43] T. Bogoslovsky, M. Spatz, A. Chaudhry, D. Maric, M. Luby, J. Frank, S. Warach,
N.N.H.o.S. Investigators, Stromal-derived factor-1[alpha] correlates with circulating
endothelial progenitor cells and with acute lesion volume in stroke patients, Stroke
42 (2011) 618–625.[44] M. Song, O. Mohamad, X. Gu, L. Wei, S.P. Yu, Restoration of intracortical and
thalamocortical circuits after transplantation of bone marrow mesenchymal stem
cells into the ischemic brain of mice, Cell Transplant. 22 (2013) 2001–2015.
[45] Y. Fan, F. Shen, T. Frenzel, W. Zhu, J. Ye, J. Liu, Y. Chen, H. Su, W.L. Young, G.Y. Yang,
Endothelial progenitor cell transplantation improves long-term stroke outcome in
mice, Ann. Neurol. 67 (2010) 488–497.
[46] M. Tsuji, A. Taguchi, M. Ohshima, Y. Kasahara, Y. Sato, H. Tsuda, K. Otani, K.
Yamahara, M. Ihara, M. Harada-Shiba, T. Ikeda, T. Matsuyama, Effects of intravenous
administration of umbilical cord blood CD34(+) cells in a mouse model of neonatal
stroke, Neuroscience 263 (2014) 148–158.
[47] V. Donega, C.T. van Velthoven, C.H. Nijboer, F. van Bel, M.J. Kas, A. Kavelaars, C.J.
Heijnen, Intranasal mesenchymal stem cell treatment for neonatal brain damage:
long-term cognitive and sensorimotor improvement, PLoS One 8 (2013), e51253.
[48] J. Forcillo, L.M. Stevens, S. Mansour, I. Prieto, R. Salem, C. Baron, D.C. Roy, E. Larose, D.
Masckauchan, N. Noiseux, Implantation of CD133+ stem cells in patients undergo-
ing coronary bypass surgery: IMPACT-CABG pilot trial, Can J. Cardiol. 29 (2013)
441–447.
[49] C. Kalka, H. Masuda, T. Takahashi, W.M. Kalka-Moll, M. Silver, M. Kearney, T. Li, J.M.
Isner, T. Asahara, Transplantation of ex vivo expanded endothelial progenitor cells
for therapeutic neovascularization, Proc. Natl. Acad. Sci. U. S. A. 97 (2000)
3422–3427.
[50] T. Yasuhara, K. Hara, M. Maki, R.W. Mays, R.J. Deans, D.C. Hess, J.E. Carroll, C.V.
Borlongan, Intravenous grafts recapitulate the neurorestoration afforded by intrace-
rebrally delivered multipotent adult progenitor cells in neonatal hypoxic-ischemic
rats, J. Cereb. Blood Flow Metab. 28 (2008) 1804–1810.
[51] C. Purandare, D.G. Shitole, V. Belle, A. Kedari, N. Bora, M. Joshi, Therapeutic potential
of autologous stem cell transplantation for cerebral palsy, Case Rep. Transplant 2012
(2012) 825289.
[52] A.E. Willing, J. Lixian, M. Milliken, S. Poulos, T. Zigova, S. Song, C. Hart, J. Sanchez-
Ramos, P.R. Sanberg, Intravenous versus intrastriatal cord blood administration in
a rodent model of stroke, J. Neurosci. Res. 73 (2003) 296–307.
[53] C.M. Cotten, A.P. Murtha, R.N. Goldberg, C.A. Grotegut, P.B. Smith, R.F. Goldstein, K.A.
Fisher, K.E. Gustafson, B. Waters-Pick, G.K. Swamy, B. Rattray, S. Tan, J. Kurtzberg,
Feasibility of autologous cord blood cells for infants with hypoxic-ischemic enceph-
alopathy, J. Pediatr. 164 (2014) 973–979 (e971).
